Printer Friendly

FDA approves single-pill HIV treatment.

SILVER SPRING, Md., U.S.A., Muharram 25, 1437, November 07, 2015, SPA -- The U.S. Food and Drug Administration announced today its approval of a new all-in-one pill to treat HIV patients that includes a new version of the drug tenofovir, which researchers think will help reduce side effects from the multi-drug regimens used for HIV, UPI reported.

The pill, called Genvoya, includes doses of elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide and is meant especially for patients over age 12 who weigh at least 77 pounds and have not previously been treated for HIV.

In addition to reducing side effects, the drug also was associated with less kidney toxicity and fewer reductions in bone density credited to other drugs that contain tenofovir. Patients who already have significant kidney problems, however, should not be treated with the drug, the agency said.

Gilead Sciences, the California-based company that developed Genvoya, conducted four clinical trials with 3,171 participants who were randomly assigned to receive either the new pill or another HIV treatment. The testing was conducted in 21 countries with a wide variety of patients, including treatment-naive, virologically suppressed, renally impaired and adolescent patients.

--SPA

02:34 LOCAL TIME 23:34 GMT

All Rights Reversed for Saudi Press Agency Provided by SyndiGate Media Inc. ( Syndigate.info ).

COPYRIGHT 2015 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Saudi Press Agency (SPA)
Date:Nov 6, 2015
Words:215
Previous Article:Two Holy Mosques' General President, his deputy, hail choosing King Salman as one of most influential figures in world.
Next Article:Wall Street Closing.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters